Statistics

Total Visits

Views
Preliminary circulating tumour cell (CTC) analysis in phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel treatment (SOGUG-CABASEM trial).44

Select a period of time:

Number of views in the range

Views
Preliminary circulating tumour cell (CTC) analysis in phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel treatment (SOGUG-CABASEM trial).26

Views

Views
January 20256
February 20252
March 202513
April 20252
May 20251
June 20252
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore13
United States4
United Kingdom2
Hong Kong2
United Arab Emirates2
Brazil1
Germany1
Spain1
 

Top cities views

Views
Hong Kong2
Council Bluffs1
Rio Claro1